KNIGHT THERAPEUTICS INC (GUD.CA) Fundamental Analysis & Valuation

TSX:GUD • CA4990531069

6.1 CAD
-0.09 (-1.45%)
Last: Mar 12, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This GUD.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to GUD. GUD was compared to 34 industry peers in the Pharmaceuticals industry. The financial health of GUD is average, but there are quite some concerns on its profitability. GUD is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. GUD.CA Profitability Analysis

1.1 Basic Checks

  • In the past year GUD has reported negative net income.
  • GUD had a positive operating cash flow in the past year.
  • In multiple years GUD reported negative net income over the last 5 years.
  • Of the past 5 years GUD 4 years had a positive operating cash flow.
GUD.CA Yearly Net Income VS EBIT VS OCF VS FCFGUD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of GUD (-0.33%) is better than 67.65% of its industry peers.
  • Looking at the Return On Equity, with a value of -0.46%, GUD is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
Industry RankSector Rank
ROA -0.33%
ROE -0.46%
ROIC N/A
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
GUD.CA Yearly ROA, ROE, ROICGUD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2 -2 4

1.3 Margins

  • GUD's Profit Margin has declined in the last couple of years.
  • GUD's Gross Margin of 42.49% is in line compared to the rest of the industry. GUD outperforms 55.88% of its industry peers.
  • GUD's Gross Margin has declined in the last couple of years.
  • The Profit Margin and Operating Margin are not available for GUD so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 42.49%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
GUD.CA Yearly Profit, Operating, Gross MarginsGUD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. GUD.CA Health Analysis

2.1 Basic Checks

  • GUD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • GUD has less shares outstanding than it did 1 year ago.
  • GUD has less shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, GUD has an improved debt to assets ratio.
GUD.CA Yearly Shares OutstandingGUD.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
GUD.CA Yearly Total Debt VS Total AssetsGUD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 2.11 indicates that GUD is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • GUD has a better Altman-Z score (2.11) than 88.24% of its industry peers.
  • GUD has a debt to FCF ratio of 37.42. This is a negative value and a sign of low solvency as GUD would need 37.42 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 37.42, GUD perfoms like the industry average, outperforming 58.82% of the companies in the same industry.
  • A Debt/Equity ratio of 0.11 indicates that GUD is not too dependend on debt financing.
  • GUD has a better Debt to Equity ratio (0.11) than 73.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 37.42
Altman-Z 2.11
ROIC/WACCN/A
WACC9.02%
GUD.CA Yearly LT Debt VS Equity VS FCFGUD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 2.62 indicates that GUD has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 2.62, GUD is in the better half of the industry, outperforming 64.71% of the companies in the same industry.
  • A Quick Ratio of 1.68 indicates that GUD should not have too much problems paying its short term obligations.
  • GUD has a better Quick ratio (1.68) than 76.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.62
Quick Ratio 1.68
GUD.CA Yearly Current Assets VS Current LiabilitesGUD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. GUD.CA Growth Analysis

3.1 Past

  • GUD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 93.10%, which is quite impressive.
  • Measured over the past years, GUD shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -13.46% on average per year.
  • The Revenue has grown by 18.70% in the past year. This is quite good.
  • GUD shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 50.87% yearly.
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%

3.2 Future

  • GUD is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.70% yearly.
  • Based on estimates for the next years, GUD will show a quite strong growth in Revenue. The Revenue will grow by 9.82% on average per year.
EPS Next Y-409.73%
EPS Next 2Y-2.05%
EPS Next 3Y41.41%
EPS Next 5Y54.7%
Revenue Next Year20.16%
Revenue Next 2Y13.94%
Revenue Next 3Y9.74%
Revenue Next 5Y9.82%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GUD.CA Yearly Revenue VS EstimatesGUD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
GUD.CA Yearly EPS VS EstimatesGUD.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.2 -0.2 0.4

More info and screens

Find the best growth stocksShow best growing peers

2

4. GUD.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GUD. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 127.15 indicates a quite expensive valuation of GUD.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of GUD is on the same level as its industry peers.
  • When comparing the Price/Forward Earnings ratio of GUD to the average of the S&P500 Index (23.82), we can say GUD is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 127.15
GUD.CA Price Earnings VS Forward Price EarningsGUD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 -100 -200 -300

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GUD is on the same level as its industry peers.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as GUD.
Industry RankSector Rank
P/FCF 212.14
EV/EBITDA 12.61
GUD.CA Per share dataGUD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as GUD's earnings are expected to grow with 41.41% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.05%
EPS Next 3Y41.41%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GUD.CA Dividend Analysis

5.1 Amount

  • GUD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GUD.CA Fundamentals: All Metrics, Ratios and Statistics

KNIGHT THERAPEUTICS INC

TSX:GUD (3/12/2026, 7:00:00 PM)

6.1

-0.09 (-1.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-19
Inst Owners16.05%
Inst Owner ChangeN/A
Ins Owners1.89%
Ins Owner ChangeN/A
Market Cap602.25M
Revenue(TTM)413.85M
Net Income(TTM)-3.49M
Analysts78
Price Target8.09 (32.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-753.57%
Min EPS beat(2)-815.07%
Max EPS beat(2)-692.08%
EPS beat(4)2
Avg EPS beat(4)-169.96%
Min EPS beat(4)-815.07%
Max EPS beat(4)461.4%
EPS beat(8)2
Avg EPS beat(8)-354.72%
EPS beat(12)5
Avg EPS beat(12)-190.89%
EPS beat(16)7
Avg EPS beat(16)-395.3%
Revenue beat(2)2
Avg Revenue beat(2)11.78%
Min Revenue beat(2)11.06%
Max Revenue beat(2)12.49%
Revenue beat(4)4
Avg Revenue beat(4)8.38%
Min Revenue beat(4)0.88%
Max Revenue beat(4)12.49%
Revenue beat(8)7
Avg Revenue beat(8)5.34%
Revenue beat(12)11
Avg Revenue beat(12)8.81%
Revenue beat(16)14
Avg Revenue beat(16)8.72%
PT rev (1m)0%
PT rev (3m)0.79%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-400%
EPS NY rev (1m)0%
EPS NY rev (3m)-9.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.13%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-0.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 127.15
P/S 1.46
P/FCF 212.14
P/OCF 16.94
P/B 0.79
P/tB 2.03
EV/EBITDA 12.61
EPS(TTM)-0.02
EYN/A
EPS(NY)0.05
Fwd EY0.79%
FCF(TTM)0.03
FCFY0.47%
OCF(TTM)0.36
OCFY5.9%
SpS4.19
BVpS7.77
TBVpS3.01
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.33%
ROE -0.46%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 42.49%
FCFM 0.69%
ROA(3y)-1.39%
ROA(5y)0.29%
ROE(3y)-1.78%
ROE(5y)0.26%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-43.41%
PM growth 5Y-47.95%
GM growth 3Y-0.3%
GM growth 5Y-3.67%
F-Score5
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.11
Debt/FCF 37.42
Debt/EBITDA 1.93
Cap/Depr 58.99%
Cap/Sales 7.91%
Interest Coverage N/A
Cash Conversion 80.91%
Profit Quality N/A
Current Ratio 2.62
Quick Ratio 1.68
Altman-Z 2.11
F-Score5
WACC9.02%
ROIC/WACCN/A
Cap/Depr(3y)40.08%
Cap/Depr(5y)130.51%
Cap/Sales(3y)6.77%
Cap/Sales(5y)24.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.1%
EPS 3Y-25.31%
EPS 5Y-13.46%
EPS Q2Q%-4850%
EPS Next Y-409.73%
EPS Next 2Y-2.05%
EPS Next 3Y41.41%
EPS Next 5Y54.7%
Revenue 1Y (TTM)18.7%
Revenue growth 3Y15.1%
Revenue growth 5Y50.87%
Sales Q2Q%31.74%
Revenue Next Year20.16%
Revenue Next 2Y13.94%
Revenue Next 3Y9.74%
Revenue Next 5Y9.82%
EBIT growth 1Y-395.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year454.5%
EBIT Next 3Y80.13%
EBIT Next 5Y55.38%
FCF growth 1Y-63.88%
FCF growth 3YN/A
FCF growth 5Y23.85%
OCF growth 1Y56.3%
OCF growth 3Y-6.66%
OCF growth 5Y51.14%

KNIGHT THERAPEUTICS INC / GUD.CA FAQ

Can you provide the ChartMill fundamental rating for KNIGHT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 4 / 10 to GUD.CA.


What is the valuation status for GUD stock?

ChartMill assigns a valuation rating of 2 / 10 to KNIGHT THERAPEUTICS INC (GUD.CA). This can be considered as Overvalued.


What is the profitability of GUD stock?

KNIGHT THERAPEUTICS INC (GUD.CA) has a profitability rating of 2 / 10.


What is the financial health of KNIGHT THERAPEUTICS INC (GUD.CA) stock?

The financial health rating of KNIGHT THERAPEUTICS INC (GUD.CA) is 6 / 10.